Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.34 |
| ▸ | FDPS | P14324 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1199287 | 1.00 | ALOX15 (0.60) | ALOX15ALDH1A1NFE2L2USP2TSHR | |
| SCHEMBL7618433 | 0.81 | USP2 (0.55) | ALOX15ALDH1A1USP2TSHRKDM4E | |
| SCHEMBL8059226 | 0.77 | ALOX15 (0.67) | ALOX15ALDH1A1NFE2L2USP2TSHR | |
| SCHEMBL8397532 | 0.77 | ALOX15 (0.67) | ALOX15ALDH1A1NFE2L2USP2TSHR | |
| SCHEMBL4861727 | 0.76 | ALOX15 (0.49) | ALOX15ALDH1A1NFE2L2USP2TSHR | |
| SCHEMBL4448966 | 0.76 | ALOX15 (0.65) | ALOX15ALDH1A1NFE2L2USP2TSHR | |
| SCHEMBL27200268 | 0.76 | ALOX15 (0.65) | ALOX15ALDH1A1NFE2L2USP2TSHR | |
| SCHEMBL14581768 | 0.76 | ALOX15 (0.65) | ALOX15ALDH1A1NFE2L2USP2TSHR | |
| SCHEMBL17955374 | 0.76 | ALOX15 (0.65) | ALOX15ALDH1A1NFE2L2USP2TSHR | |
| SCHEMBL6191964 | 0.76 | ALOX15 (0.56) | ALOX15ALDH1A1USP2TSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113880737-B | Application of novel persulfate reagent in synthesis of asymmetric polysulfide | 安徽农业大学 | 2023-09-15 | — | — | CN | disclosed |
| CN-113880737-A | Application of novel persulfur reagent in synthesis of asymmetric persulfur | 安徽农业大学 | 2022-01-04 | — | — | CN | disclosed |
| US-20110039899-A1 | Gabapentin for the Treatment of Overactive Bladder, Stress Incontinence and BPH | PFIZER INC | 2011-02-17 | — | — | US | disclosed |
| US-5506345-A | ANTIHYPOXIC AGENTS | AMERSHAM INTERNATIONAL PLC (GB) | 1996-04-09 | — | — | US | disclosed |
| US-5387692-A | A bisamine oxime compound containing a 2-nitroimidazole group | AMERSHAM INTERNATIONAL PLC (GB) | 1995-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039899-A1 | Gabapentin for the Treatment of Overactive Bladder, Stress Incontinence and BPH | GABRB2, GABRB3, GABRB1 | ALOX15 2292/4885ALDH1A1 581/4885NFE2L2 866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.